SCHEMBL19299708

SCHEMBL19299708

CC(C)c1ccc(OCC(=O)NNC(=O)/C=C/c2cc3ccccc3o2)cc1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.51
TDP1 Q9NUW8 3/20 0.51
MAPT P10636 5/20 0.50
KMT2A Q03164 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
CYP1A2 P05177 1/20 0.47
CYP2C19 P33261 1/20 0.47
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 1/20 0.47
MEN1 O00255 1/20 0.46
TAAR1 Q96RJ0 1/20 0.46
HPGD P15428 1/20 0.46
PLIN1 O60240 1/20 0.45
LMNA P02545 1/20 0.45
GAA P10253 1/20 0.45
MAPK1 P28482 1/20 0.45
PLIN5 Q00G26 1/20 0.45
ABHD5 Q8WTS1 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19299709 0.92 UBE2N (0.52) POLBTDP1MAPTKMT2AL3MBTL1
SCHEMBL19299697 0.75 POLB (0.63) POLBTDP1MAPTKMT2AL3MBTL1
SCHEMBL19294530 0.72 KDM4E (0.56) POLBTDP1MAPTKMT2AL3MBTL1
SCHEMBL10554653 0.70 RAB9A (0.59) TDP1MAPTKMT2AALDH1A1MEN1
SCHEMBL17541852 0.70 MAOB (0.60) TDP1MAPTKMT2AKDM4EALDH1A1
SCHEMBL17541850 0.70 MAOB (0.60) TDP1MAPTKMT2AKDM4EALDH1A1
SCHEMBL3209446 0.70 RAB9A (0.62) TDP1MAPTKMT2AALDH1A1MEN1
SCHEMBL3209460 0.70 RAB9A (0.62) TDP1MAPTKMT2AALDH1A1MEN1
SCHEMBL6070874 0.69 MAPT (0.58) TDP1MAPTKMT2AL3MBTL1KDM4E
SCHEMBL6070869 0.69 MAPT (0.58) TDP1MAPTKMT2AL3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3212183-B1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS UNIV ROCHESTER (US) 2019-10-02 EP disclosed
US-10028931-B2 Synergistic compositions for treating microbial infections UNIVERSITY OF ROCHESTER (US) 2018-07-24 US disclosed
US-20170246139-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS UNIVERSITY OF ROCHESTER (US) 2017-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10028931-B2 Synergistic compositions for treating microbial infections RNASE1, RNASEL, RNASEH1 POLB 340/4885TDP1 448/4885MAPT 4406/4885
US-20170246139-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS RNASE1, RNASEL, RNASEH1 POLB 340/4885TDP1 448/4885MAPT 4406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.